<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525729</url>
  </required_header>
  <id_info>
    <org_study_id>RITA</org_study_id>
    <nct_id>NCT04525729</nct_id>
  </id_info>
  <brief_title>Rituximab and RASi in Patients With IgAN</brief_title>
  <acronym>RITA</acronym>
  <official_title>A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHENNAN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dongfang Hospital Affiliated to Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pudong New Area People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital North Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Municipal Yinzhou District No.2 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiamen Hongai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in&#xD;
      combination with RASi(ACEI and/or ARB) compared with RASi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IgA nephropathy (IgAN, IgA nephropathy), is currently the most common glomerular disease&#xD;
      worldwide, which is characterized by High population quantity, wide distribution, strong&#xD;
      heterogeneity.&#xD;
&#xD;
      Diagnosis of Urinary protein control level within 1 year is one of the important predictors&#xD;
      of renal failure in IgAN patients.Previous studies have shown that patients with renal&#xD;
      insufficiency, hypertension, or urinary protein &gt; 1g at 24h during renal biopsy, and those&#xD;
      with poor urinary protein control within 1 year of follow-up, have a higher risk of disease&#xD;
      progression, and more than 30-50% of patients will develop into end-stage renal disease&#xD;
      (ESRD) within 10 years.&#xD;
&#xD;
      The recommended treatments for IgAN in the KDIGO guidelines include: RASi, glucocorticoid,&#xD;
      immunosuppressor, antiplatelet drugs, lipid-lowering drugs, etc. Several trials have&#xD;
      demonstrated the benefit of RASi in retarding disease progression in IgAN patients with&#xD;
      proteinuria, but there is currently no specific treatment for IgAN.&#xD;
&#xD;
      In recent years, it has been found that excessive production of Galactos-deficient IgA1 is&#xD;
      one of the initiating factors of the pathogenesis of IgAN. Infection by pathogenic&#xD;
      microorganisms induces lymphocytes in IgAN patients to produce anti-GD-IgA1 autoantibodies&#xD;
      (second strike), which forms circulating immune complexes to deposit in the kidney and&#xD;
      activates complement, which is an important pathogenesis of IgAN.However, recent studies have&#xD;
      suggested that B-cell depletion therapy is effective for many aabs mediated renal diseases&#xD;
      (e.g., membranous nephropathy, lupus nephritis, etc.). Rituximab, which combined with CD20&#xD;
      antigen on the B cell surface, can deplete B cells and play a therapeutic role by reducing&#xD;
      antibody production. Therefore, the treatment of rituximab has potential therapeutic value&#xD;
      for IgAN patients as well.&#xD;
&#xD;
      However, there were very few studies which have shown the efficacy and safety of rituximab in&#xD;
      the treatment of IgA nephropathy, only groups reported abroad, and the results were&#xD;
      inconsistent. At present, there have been no randomized controlled studies to verify the&#xD;
      safety and efficacy of rituximab in the treatment of IgA nephropathy, especially in Chinese&#xD;
      with high incidence of IgAN.&#xD;
&#xD;
      In this study, treatment of rituximab combining with RASi will be compared with RASi for IgAN&#xD;
      patients, to explore an effective and safer regimen for IgAN, so as to bring more hope to&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in proteinuria levels over 1 year compared with baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Primary outcome included changes in proteinuria levels over 1 year compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of 50% reduction in mean urinary protein compared with baseline over 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Statistical data of proportion of 50% reduction in mean urinary protein compared with baseline over 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of 50% reduction in mean urinary protein compared with baseline over 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Statistical data of proportion of 50% reduction in mean urinary protein compared with baseline over 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proteinuria levels over 6 months compared with baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary Outcome included changes in proteinuria levels over 6 months compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in eGFR levels over 1 year compared with baseline</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the efficacy of treatment in renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gd-IgA1 levels</measure>
    <time_frame>1 year</time_frame>
    <description>To observe the changes in GD-IGA1 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Record the safety of Interventional drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ESRD</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the efficacy of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of 50% reduction in eGFR levels or doubling serum creatinine compared with baseline</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the safety of Rituximab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Rituximab+RASi(ACEI and/or ARB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RASi(ACEI and/or ARB）</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.</description>
    <arm_group_label>Rituximab+RASi(ACEI and/or ARB)</arm_group_label>
    <other_name>HLX01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAS 2410</intervention_name>
    <description>To evaluate the efficacy and safety of RASi in patients with IgAN.</description>
    <arm_group_label>RASi(ACEI and/or ARB）</arm_group_label>
    <arm_group_label>Rituximab+RASi(ACEI and/or ARB)</arm_group_label>
    <other_name>No specific restrictions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. 18 to 75 of age, male or female;&#xD;
&#xD;
          -  2. primary IgA nephropathy confirmed by renal biopsy&#xD;
&#xD;
          -  3. eGFR&gt;30ml/min/1.73m2(calculated according to the CKD-EPI formula);&#xD;
&#xD;
          -  4. After using maximum tolerated doses of ACEI and/or ARB for 3 months, the following&#xD;
             two points should be met:&#xD;
&#xD;
               1. 24h proteinuria ≥1g;&#xD;
&#xD;
               2. Bp&lt;130/80 mmHg；&#xD;
&#xD;
          -  5. Serum albumin &gt; 25g/L;&#xD;
&#xD;
          -  6. Sign the informed consent.&#xD;
&#xD;
        Note : It is suggested that active IgAN patients should be selected. Active IgAN is&#xD;
        specifically defined as conforming to any of the following :&#xD;
&#xD;
          1. ) intradermal augmentation ( E1 ),&#xD;
&#xD;
          2. ) crescentic body 0 - 50 % ( C1 / C2 ),&#xD;
&#xD;
          3. ) fibrinoid necrosis,&#xD;
&#xD;
          4. ) more interstitial inflammatory cell infiltration. At the same time, the proportion&#xD;
             of sclerosis was low ( spherical or segmental sclerosis ball &lt; 50 % ), and&#xD;
             interstitial fibrosis was low ( below T2 ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Evidence of the use of glucocorticoids for immunosuppressive therapy, such as:&#xD;
             nephrotic syndrome, pathology for small lesions with IgA nephropathy. or the&#xD;
             proportion of crescents confirmed by renal biopsy within 12 months was more than 50 %.&#xD;
&#xD;
          -  2. Clinical confirmation of cirrhosis, chronic active liver disease, or hepatitis B,&#xD;
             C, or HIV which can detect viral replication;&#xD;
&#xD;
          -  3. Clinically confirmed IgA nephropathy secondary to systemic diseases such as&#xD;
             systemic lupus erythematosus, allergic purpura.&#xD;
&#xD;
          -  4. Patients with non-simple IgA nephropathy, such as diabetic nephropathy or&#xD;
             obesity-related nephropathy.&#xD;
&#xD;
          -  5. A history of active systemic infection or severe infection occurred one month&#xD;
             before enrollment.&#xD;
&#xD;
          -  6. Those who are pregnant or lactating or unwilling to take contraceptive measures.&#xD;
&#xD;
          -  7. Current or recent ( within 30 days ) exposure to any research drug.&#xD;
&#xD;
          -  8. Patients with allergic reactions to rituximab and / or known allergic reactions.&#xD;
&#xD;
          -  9. Laboratory tests meeting the following criteria should be excluded:&#xD;
&#xD;
             (1) Hemoglobin &lt;80g/L; (2) Platelet &lt;80×10^9/L; (3) Neutrophils &lt; 1.0×10^9/L; (4)&#xD;
             Aspartic acid aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5× normal&#xD;
             upper limit, except for the correlation with the primary disease;&#xD;
&#xD;
          -  10. Continuous use of hormones or other immunosuppressive therapy in the past 6&#xD;
             months;&#xD;
&#xD;
          -  11. Accompanying or past malignant tumors, except for fully treated skin basal or&#xD;
             squamous cell carcinoma or cervical carcinoma in situ;&#xD;
&#xD;
          -  12. History of psychosis may interfere with normal participation in this study;&#xD;
&#xD;
          -  13. Patients with major heart or lung diseases (including obstructive pulmonary&#xD;
             disease);&#xD;
&#xD;
          -  14. In acute and chronic tuberculosis infection period (tuberculin test positive,&#xD;
             chest X-ray suspected tuberculosis patients);&#xD;
&#xD;
          -  15. Patients with history of immunodeficiency, including other acquired or congenital&#xD;
             immunodeficiency diseases, or a history of organ transplantation;&#xD;
&#xD;
          -  16. Weight less than 50kg should be excluded;&#xD;
&#xD;
          -  17. Other researchers judge the patients unsuitable for inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingyuan Xie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Chen</last_name>
    <phone>13601638963</phone>
    <phone_ext>+86</phone_ext>
    <email>cnrj100@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyuan Xie</last_name>
    <phone>13761056656</phone>
    <phone_ext>+86</phone_ext>
    <email>nephroxie@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan Chen</last_name>
      <phone>13601638963</phone>
      <email>cnrj100@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>CHENNAN</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>IgAN</keyword>
  <keyword>Rituximab</keyword>
  <keyword>RASi</keyword>
  <keyword>Gd-IgA1</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

